Rivastigmine for dementia associated with Parkinson's disease.
Morgan
John
J
Department of Neurology, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912, USA.
Sethi
Kapil D
KD
D000368:Aged; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D003704:Dementia / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000209:etiology; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D010300:Parkinson Disease / Q000150:complications*; D018579:Patient Selection; D048448:Phenylcarbamates / Q000008:administration & dosage* / Q000009:adverse effects*; D011446:Prospective Studies; D000068836:Rivastigmine; D016896:Treatment Outcome; D014202:Tremor / Q000139:chemically induced / Q000503:physiopathology; D014839:Vomiting / Q000139:chemically induced
D002800:Cholinesterase Inhibitors; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine